Burkitt Lymphoma · line 2 · R-ICE (Rituximab + Ifosfamide + Carboplatin + Etoposide) × 2-3 cycles → ASCT in CR2 (r/r Burkitt salvage)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-RICE-BURKITT |
| ID | IND-BURKITT-2L-RICE-ASCT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-BURKITT |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for r/r Burkitt. Rapid intervention critical — natural history catastrophic at relapse. ASCT consolidation in CR2 is goal; alloSCT for primary-refractory or post-ASCT relapse.
Used By
Algorithms
ALGO-BURKITT-2L- ALGO-BURKITT-2L